Indonesia is poised to secure COVID-19 vaccines from Pfizer and AstraZeneca, the health minister said on Tuesday, as it awaits authorisation to begin an inoculation drive with China's Sinovac.
Budi Gunadi Sadikin said a 50-million-dose deal with AstraZeneca would be finalised before the end of the year, and one of the same size with Pfizer in the first week of January.
The first shots for both those drugs, which have gained regulatory approval in many western countries, are not scheduled to arrive for months, the minister added.
Indonesia plans to start vaccinations with the Sinovac treatment, of which it secured 1.2 million doses this month and expects 1.8 million more in January, once it gains emergency use clearance.
Interim results from its phase III trial are expected to be delivered to Indonesia's Food and Drug Agency next month.
Budi said the country's 1.3 million frontline health workers would get priority in the first wave of vaccinations between January and April. "They are the most important group of people in our battle against the pandemic," he told a news conference.
The world's fourth most populous country has had over 727,000 confirmed COVID cases and 21,700 deaths, among Asia's highest tallies.
Public servants will be next in line for shots, with those in infection "red-zones" aged between 18 and 59 prioritised in a second round of vaccinations.
Indonesia is focusing its programme on that age range rather than the elderly in an effort to safeguard the working population.
Bambang Heriyanto, corporate secretary of state-owned drugmaker Bio Farma, said strategy would allow Indonesia to reach herd immunity.
Including Tuesday's announcement, Indonesia has secured 329 million vaccine doses, including about 125 million from Sinovac, 50 million from Novavax and 54 million from global vaccine programme COVAX.
The AstraZeneca vaccines are expected to arrive in the second quarter of 2021 and Pfizer's in the third quarter, according to a slide presentation by Budi.
The companies were not immediately available for comment.